The size of the Global Anti-neoplastic Agents Market is estimated to grow at a CAGR of 8.3% from 2019 to 2024. Anti-neoplastic agents are drugs that are used as the primary treatment of patients suffering from cancer.
MARKET DRIVERS
Increasing incidences of cancer cases among the people are one major factor that boosts the market growth.
According to the Center for Disease Control and Prevention (CDC), malignant neoplasms accounted for 15% of deaths across the world with 19.3 million new cases of cancer is considered to be diagnosed by 2025. As a paradigm, the reports according to the Healthcare Cost and Utilization Project (H-cup) there were 4.7 million hospitalizations associated with cancer in the U.S. and around 6% of the adult population of inpatient hospital cost was caused due to hospitalization of patients with cancer.
Additionally, advance technologies that are used up in the anti-neoplastic agents market are one such factor that propels the Anti-neoplastic Agents Market growth. Also, investments made by private organizations for the manufacturing of the drugs related to cancer and other diseases are also accelerating the market growth. Grong requirement for the anti-neoplastic pharmaceutical agents that has dragged the attention of pharmaceutical industries to get into the market for developing and manufacturing more productive drugs for fighting against cancer conditions which is one of the factors that drive the market growth.
MARKET RESTRAINTS
Absenteeism of preset the regulatory frameworks that are considerably hampering the market growth. Moreover, some adverse effects will be raised up that are associated with neoplastic agents are to hinder the market growth. Strict rules to follow by the top companies in producing drugs is likely to obstruct the market growth. Also, the need for FDA approvals for the drug release into the market is restraining the Anti-neoplastic Agents Market growth.
Lack of knowledge about cancer in people is impeding market growth. Diverse nature of cancer and also the cost related to the development is high are some of the factors that are limiting the growth. Technical Complications that are related to the existing diagnostic tests are the factors that restrain the Anti-neoplastic Agents Market growth.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 - 2024 |
|
Segments Covered |
By-Products, End Users and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This research report on the Global Anti-neoplastic Agents Market segmented and sub-segmented based on the products, end-users and region.
Anti-neoplastic Agents Market– By Product:
On the basis of product, the chemotherapeutic agent segment accounts for a major share of the market revenue.
Anti-neoplastic Agents Market – By End Users:
On the basis of end-users, the Hospital segment dominated a major share of the market revenue.
Regional Analysis:
The Global Anti-neoplastic Agents market was dominated by North America closely followed Europe. Asia Pacific is expected to grow at a high CAGR.
North America region is dominating and is holding the largest share of anti-neoplastic agents market that is due to the common increase of contagious diseases, the appearance of highly developed healthcare are some of the factors that drive this region forward.
Europe is regarded to be the second-largest market share in anti-neoplastic agents. According to the Cancer Research of UK, 605 people 100,000 general populations are diagnosed with cancer. In this region countries like the UK and Germany are considered to notice high acceptance for anti-cancer drugs when compared with others.
Asia-pacific is likely to notice the development at a higher rate. In this region countries like Japan and Australia are considered to have favourable market development. China and India are considered to be the most attractive market due to the high incidences of the syndrome and the existence of key market players.
Top companies leading the Global Anti-neoplastic Agents Market profiled in this report are Aspen Global Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Pvt. Ltd., Merck & Co., Inc., Pfize Inc., Hoffmann-La Roche Ltd., Amgen Inc., Bristol-Myers Squibb Company, Baxter Healthcare Corporation, Boehringer Ingelheim GmbH, Accord Healthcare, Inc., Genentech, Inc., Lundbeck LLC and AbbVie Inc.
Genentech, one of the top leading companies, has been approved by the FDA for the acceptance of atezolizumab that is the treatment used by the patient suffering from metastatic non-small lung cancer for those whose tumour is high with PD-L1 expression.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Chemotherapeutic agent
5.1.3 Biological agents
5.1.4 Personalied medicine
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 End user
5.2.1 Introduction
5.2.2 Hospitals
5.2.3 Clinics
5.2.4 Cancer rehabilitaion centers
5.2.5 Ambulatory surgical centers
5.2.6 Y-o-Y Growth Analysis, By end user
5.2.7 Market Attractiveness Analysis, By end user
5.2.8 Market Share Analysis, By end user
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By end user
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By end user
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By end user
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Hoffmann-La Roche Ltd
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Amgen Inc.
8.3 Bristol-Myers Squibb Company
8.4 Baxter Healthcare Corporation
8.5 Boehringer Ingelheim GmbH
8.6 Aspen Global Inc.
8.7 Bayer AG
8.8 Teva pharmaceutical Industries Ltd.
8.9 Johnson & Johnson Pvt. Ltd.
8.10 Accord Healthcare, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
